Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
881 stopped studies mapped to Malignant Intestinal Neoplasm and descendants · 90% state a reason
Over the 881 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06675513 | Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer | Early Phase 1 | suspended | Nov 5, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in…(PANEL) | N/A | terminated | Jan 27, 2016 | University Hospital, Rouen | Difficulty in enrolling patients | Enrollment / accrual |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES… | N/A | suspended | Jun 18, 2021 | Rutgers, The State University of New Jersey | Pending Protocol amendment | Other (stated, no rule matched) |
| NCT04336202 | Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy(Whistle) | N/A | suspended | Apr 7, 2020 | Sir Mortimer B. Davis - Jewish General Hospital | Issues with applicator | Other (stated, no rule matched) |
| NCT03876561 | "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low…(CONTICARE) | N/A | terminated | Mar 15, 2019 | Nantes University Hospital | lack of inclusion | Other (stated, no rule matched) |
| NCT04101292 | Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours… | N/A | withdrawn | Sep 24, 2019 | IHU Strasbourg | Problems with the provision of equipment encountered during the study could not be resolved, making… | Other (stated, no rule matched) |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109…(TEJAS-2) | Phase 2 | terminated | Jan 7, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | Phase 1 / Phase 2 | terminated | May 30, 2014 | Cancer Trials Ireland | Due to futility | Efficacy / futility |
| NCT07479381 | Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study(CLEAR) | — | terminated | Mar 18, 2026 | Harbinger Health | Study terminated per sponsor decision due to operational reasons. The termination was not a result… | Safety / toxicity |
| NCT06034197 | Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy | Early Phase 1 | terminated | Sep 13, 2023 | Stephan Rogalla | The drug supply expired and the sponsor is unable to provide an updated supply. | Drug supply |
| NCT06152523 | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer(MONAMI) | Phase 2 | withdrawn | Nov 30, 2023 | Assistance Publique - Hôpitaux de Paris | The study has been halted because the manufacturer can no longer supply the experimental treatment | Drug supply |
| NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor… | Phase 2 | withdrawn | Apr 6, 2026 | NGM Biopharmaceuticals, Inc | Study terminated by Sponsor | Other (stated, no rule matched) |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | Phase 2 | withdrawn | Nov 18, 2024 | Eric Jacobsen, MD | Ipsen requested a temporary closure due to a safety concern. | Safety / toxicity |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04523389 | Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients(ExoColon) | — | terminated | Aug 21, 2020 | Centre Hospitalier Universitaire Dijon | As the laboratory due to carry out the biological analyses withdrew, the project did not go ahead | Other (stated, no rule matched) |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06181201 | Association Between the Composition of the Intestinal Microbiota and Tumor Response in…(Neo-Flo-Rect) | — | terminated | Dec 26, 2023 | Centre Oscar Lambret | Lack of eligible patients | Other (stated, no rule matched) |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative…(NeuroPrevPTSD) | Phase 2 | terminated | Aug 29, 2018 | Centre Oscar Lambret | Lack of recruitment and of study staff | Enrollment / accrual |
| NCT07137390 | A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With… | Phase 1 / Phase 2 | withdrawn | Aug 22, 2025 | M.D. Anderson Cancer Center | 0 participants enrolled | Enrollment / accrual |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Phase 2 | terminated | Nov 18, 2019 | National Cancer Institute (NCI) | Interim analysis indicated limited efficacy | Efficacy / futility |
| NCT00748449 | Colonography Versus Colonoscopy in High Risk Patient(COLO-TDM) | N/A | terminated | Sep 8, 2008 | Assistance Publique - Hôpitaux de Paris | No more inclusions | Other (stated, no rule matched) |
| NCT06281925 | Cryotherapy & Oxaliplatin | N/A | suspended | Feb 28, 2024 | NYU Langone Health | Study paused to enrollment | Enrollment / accrual |
| NCT06292975 | Exercise for Improving Radiotherapy Efficacy in Rectal Cancer | N/A | withdrawn | Mar 5, 2024 | University of Hull | Although patients were screened, only two met the eligibility criteria within the available… | Enrollment / accrual |
| NCT07223567 | A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing… | Phase 2 | withdrawn | Nov 3, 2025 | M.D. Anderson Cancer Center | 0 participants enrolled | Enrollment / accrual |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT05983367 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in… | Phase 2 | terminated | Aug 9, 2023 | Inspirna, Inc. | At the time of the primary analysis, results did not meet the primary endpoint | Other (stated, no rule matched) |
| NCT06603818 | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in… | Phase 2 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | The trial is closing due to findings from a related study, prompting the sponsor to discontinue… | Other (stated, no rule matched) |
| NCT02738606 | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver… | Phase 2 | terminated | Apr 14, 2016 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT06501989 | Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer | Phase 2 | withdrawn | Jul 15, 2024 | Inova Health Care Services | Principal Investigator has left Inova | Investigator |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT07323576 | A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in…(INAVO-CRC) | Phase 2 | withdrawn | Jan 7, 2026 | Hoffmann-La Roche | Sponsor's decision | Sponsor / business decision |
| NCT02724202 | Curcumin in Combination With 5FU for Colon Cancer | Early Phase 1 | terminated | Mar 31, 2016 | Baylor Research Institute | PI-Initiated study; PI requested closure | Other (stated, no rule matched) |
| NCT04990895 | A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys | N/A | terminated | Aug 5, 2021 | AHS Cancer Control Alberta | Slow study accrual. Study sponsor decided to terminate the study in consultation with the DSMB. | Enrollment / accrual |
| NCT05062889 | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon…(ERASE-CRC) | Phase 2 | suspended | Sep 30, 2021 | Gruppo Oncologico del Nord-Ovest | due to earlier termination of the agreement between the Sponsor and Central Laboratory for… | Enrollment / accrual |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients… | Phase 2 | terminated | Feb 17, 2023 | Replimune, Inc. | Business reasons. | Sponsor / business decision |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Phase 1 | terminated | Jun 13, 2024 | Pheon Therapeutics | The study was terminated by Sponsor for strategic reasons. | Sponsor / business decision |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | Phase 2 | terminated | Aug 23, 2023 | Anwaar Saeed | Terminated per directive from Bayer due to funding. | Funding |
| NCT05329870 | Does Genetic Susceptibility for Bleeding Affect Quantitative Faecal Immunochemical Test… | — | withdrawn | Apr 15, 2022 | University of Edinburgh | never started due to funding/staffing issues | Funding |
| NCT03275974 | Glutamine PET Imaging Colorectal Cancer | Phase 1 | terminated | Sep 8, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03844750 | Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and… | Phase 2 | terminated | Feb 18, 2019 | Chloe Atreya, MD, PhD | Sponsor decision | Sponsor / business decision |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | Phase 2 | terminated | Mar 21, 2022 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05241210 | Real-Time Feedback (RTFB) to Improve Colonoscopy | N/A | suspended | Feb 15, 2022 | University of Minnesota | we are on hold and may restart depending on a manual followed by automated assessment of existing… | Other (stated, no rule matched) |
| NCT05358704 | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer | Phase 2 | suspended | May 3, 2022 | Rutgers, The State University of New Jersey | no slots available | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 7, 2026source: clinicaltrials